|
1
|
McComb S, Thiriot A, Akache B, Krishnan L
and Stark F: Introduction to the immune system. Methods Mol Biol.
2024:1–24. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Parkin J and Cohen B: An overview of the
immune system. Lancet. 357:1777–1789. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pandiella-Alonso A, Diaz-Rodriguez E and
Sanz E: Antitumoral properties of the nutritional supplement ocoxin
oral solution: A comprehensive review. Nutrients.
12(2661)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gomez EV, Perez YM, Sanchez HV, Forment
GR, Soler EA, Bertot LC, Garcia AY, del Rosario Abreu Vazquez M and
Fabian LG: Antioxidant and immunomodulatory effects of Viusid in
patients with chronic hepatitis C. World J Gastroenterol.
16:2638–2647. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Vilar Gomez E, Sanchez Rodriguez Y, Torres
Gonzalez A, Calzadilla Bertot L, Arus Soler E, Martinez Perez Y,
Yasells Garcia A and Abreu Vazquez Mdel R: Viusid, a nutritional
supplement, increases survival and reduces disease progression in
HCV-related decompensated cirrhosis: A randomised and controlled
trial. BMJ Open. 1(e000140)2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vilar Gomez E, Gra Oramas B, Soler E,
Llanio Navarro R and Ruenes Domech C: Viusid, a nutritional
supplement, in combination with interferon alpha-2b and ribavirin
in patients with chronic hepatitis C. Liver Int. 27:247–259.
2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Vilar Gomez E, Rodriguez De Miranda A, Gra
Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L,
Yasells Garcia A and Del Rosario Abreu Vazquez M: Clinical trial: A
nutritional supplement Viusid, in combination with diet and
exercise, in patients with nonalcoholic fatty liver disease.
Aliment Pharmacol Ther. 30:999–1009. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Diaz-Rodriguez E, El-Mallah AM, Sanz E and
Pandiella A: Antitumoral effect of Ocoxin in hepatocellular
carcinoma. Oncol Lett. 14:1950–1958. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Diaz-Rodriguez E, Hernandez-Garcia S, Sanz
E and Pandiella A: Antitumoral effect of Ocoxin on acute myeloid
leukemia. Oncotarget. 7:6231–6242. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Diaz-Rodriguez E, Sanz E and Pandiella A:
Antitumoral effect of Ocoxin, a natural compound-containing
nutritional supplement, in small cell lung cancer. Int J Oncol.
53:113–123. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hernandez-Garcia S, Gonzalez V, Sanz E and
Pandiella A: Effect of oncoxin oral solution in HER2-overexpressing
breast cancer. Nutr Cancer. 67:1159–1169. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hernandez-SanMiguel E, Gargini R, Cejalvo
T, Segura-Collar B, Núñez-Hervada P, Hortigüela R,
Sepúlveda-Sánchez JM, Hernández-Laín A, Pérez-Núñez A, Sanz E and
Sánchez-Gómez P: Ocoxin modulates cancer stem cells and M2
macrophage polarization in glioblastoma. Oxid Med Cell Longev.
2019(9719730)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hernandez-Unzueta I, Benedicto A, Olaso E,
Sanz E, Viera C, Arteta B and Márquez J: Ocoxin oral
solution® as a complement to irinotecan chemotherapy in
the metastatic progression of colorectal cancer to the liver. Oncol
Lett. 13:4002–4012. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hernandez-Unzueta I, Benedicto A, Romayor
I, Herrero A, Sanz E, Arteta B, Olaso E and Márquez J: Ocoxin oral
solution exerts an antitumoral effect in pancreatic cancer and
reduces the stromal-mediated chemoresistance. Pancreas. 48:555–567.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Perez-Pena J, Diaz-Rodriguez E, Sanz E and
Pandiella A: Central role of cell cycle regulation in the
antitumoral action of ocoxin. Nutrients. 11(1068)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rusu RA, Sirbu D, Curseu D, Năsui B, Sava
M, Vesa ŞC, Bojan A, Lisencu C and Popa M: Chemotherapy-related
infectious complications in patients with Hematologic malignancies.
J Res Med Sci. 23(68)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vento S and Cainelli F: Infections in
patients with cancer undergoing chemotherapy: Aetiology,
prevention, and treatment. Lancet Oncol. 4:595–604. 2003.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z,
Zhang Z, You H, Wu M, Zheng Q, et al: Patients with cancer appear
more vulnerable to SARS-CoV-2: A multicenter study during the
COVID-19 outbreak. Cancer Discov. 10:783–791. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fuentes-Antras J, Manzano A, Marquina G,
Paz M, Aguado C, Granja M, Benítez J, Ortega J, Priego A, González
C, et al: A snapshot of COVID-19 infection in patients with solid
tumors. Int J Cancer: Dec 3, 2020 (Epub ahead of print). doi:
10.1002/ijc.33420.
|
|
20
|
Bouvard V, Baan R, Straif K, Grosse Y,
Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C,
Galichet L, et al: A review of human carcinogens-Part B: Biological
agents. Lancet Oncol. 10:321–322. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fernandez AF and Esteller M: Viral
epigenomes in human tumorigenesis. Oncogene. 29:1405–1420.
2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Diaz-Rodriguez E and Pandiella A:
Modulation of cereblon levels by anti-myeloma agents. Leuk
Lymphoma. 57:167–176. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Diaz-Rodriguez E, Álvarez-Fernández S,
Chen X, Paiva B, López-Pérez R, García-Hernández JL, San Miguel JF
and Pandiella A: Deficient spindle assembly checkpoint in multiple
myeloma. PLoS One. 6(e27583)2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Al-Mahtab M, Akbar SM, Khan MS and Rahman
S: Increased survival of patients with end-stage hepatocellular
carcinoma due to intake of ONCOXIN(R), a dietary supplement. Indian
J Cancer. 52:443–446. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gray Lovio OR, Abreu Daniel A, García
Yánez LA, Rodríguez MO, González CV, Lence Anta JJ and Sanz E:
Efficacy and safety of oncoxin-viusid, a nutritional supplement, in
twenty patients with stage IIB-III of cutaneous melanoma: An
open-label proof of concept study. J Cancer Sci Ther. 11:263–268.
2019.
|
|
26
|
Rivas IC, Silva JA, Alfonso G, Candanedo
H, Cuervo Y, Mestre B, Mestre Cabello JR, Lence J, Lugoyo M and
Sanz E: Oncoxin-viusid with radiotherapy and chemotherapy in
patients with head and neck cancer: Results from a phase II,
randomised, double-blind study. J Cancer Sci Ther. 10:317–327.
2018.
|
|
27
|
Fundora Ramos MI, Maden LB, Casanova FO,
Cruz FH, Reyes CS, Gato AH, Lyncon IB, González EV, Morales KP,
Lence JJ and Sanz E: Oncoxin-Viusid® may improve quality
of life and survival in patients with hormone-refractory prostate
cancer undergoing onco-specific treatments. Mol Clin Oncol.
14(5)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ruiz Lorente R, Hernández Durán D, García
Viamontes J, Lence Anta J, Ortiz Reyes R and Sanz E: Efficacy of
Oncoxin-viusid on the reduction of adverse reactions to
chemotherapy and radiotherapy in patients diagnosed with cervical
cancer and endometrial adenocarcinoma. J Cancer Ther. 11:276–295.
2020.
|
|
29
|
Uddin D, Islam MA, Mahmood I, Ghosh AK,
Khatun RA and Kundu S: Findings of the 3-month supportive treatment
with ocoxin solution beside the standard modalities of patients
with different neoplastic diseases. TAJ. 22:172–175. 2009.
|
|
30
|
Kaidarova DR, Kopp MV, Pokrovsky VS,
Dzhugashvili M, Akimzhanova ZM, Abdrakhmanov RZ, Babich EN, Bilan
EV, Byakhov AV, Gurov SN, et al: Multicomponent nutritional
supplement Oncoxin and its influence on quality of life and therapy
toxicity in patients receiving adjuvant chemotherapy. Oncol Lett.
18:5644–5652. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ashraf S, Alam J, Sarkar JA, Khondaker FA,
Farhana Y and Khan NA: An open-label randomized clinical study to
compare the effects of a nutritional supplement versus vitamin E on
fibroscan score in nonalcoholic steatohepatitis (NASH) patients.
Univ J Public Health. 6:56–62. 2018.
|
|
32
|
Pascal R and Russu E: ‘Viusud’ as a
immnunomodultaor drug for the treatment of immunological
disturbances in psoriatic arthritis. Arta Medica. 4:38–42.
2006.
|
|
33
|
Valencia MH, Pacheco AC, Quijano TH, Girón
AV and López CV: Clinical response to glycyrrhizinic acid in
genital infection due to human papillomavirus and low-grade
squamous intraepithelial lesion. Clin Pract. 1(e93)2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
de Martel C, Georges D, Bray F, Ferlay J
and Clifford GM: Global burden of cancer attributable to infections
in 2018: A worldwide incidence analysis. Lancet Glob Health.
8:e180–e190. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Plummer M, de Martel C, Vignat J, Ferlay
J, Bray F and Franceschi S: Global burden of cancers attributable
to infections in 2012: A synthetic analysis. Lancet Glob Health.
4:e609–e616. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Schelhaas M: Viruses and cancer: Molecular
relations and perspectives. Biol Chem. 398:815–816. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Dominguez Gomez J, Simon RD, Abreu Daniel
A and Zelenkova H: Effectiveness of glycyrrhizinic Acid (glizigen)
and an immunostimulant (viusid) to treat anogenital warts. ISRN
Dermatol. 2012(863692)2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Bae M and Kim H: Mini-review on the roles
of vitamin C, vitamin D, and selenium in the immune system against
COVID-19. Molecules. 25(5346)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Menegazzi M, Campagnari R, Bertoldi M,
Crupi R, Di Paola R and Cuzzocrea S: Protective effect of
epigallocatechin-3-gallate (EGCG) in diseases with uncontrolled
immune activation: Could such a scenario be helpful to counteract
COVID-19? Int J Mol Sci. 21(5171)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mhatre S, Srivastava T, Naik S and
Patravale V: Antiviral activity of green tea and black tea
polyphenols in prophylaxis and treatment of COVID-19: A review.
Phytomedicine. 85(153286)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Mrityunjaya M, Pavithra V, Neelam R,
Janhavi P, Halami PM and Ravindra PV: Immune-boosting, antioxidant
and anti-inflammatory food supplements targeting pathogenesis of
COVID-19. Front Immunol. 11(570122)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lammi C and Arnoldi A: Food-derived
antioxidants and COVID-19. J Food Biochem.
45(e13557)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Benites W, Heras MV, Mero ML and Marquez
D: Effectiveness of VIUSID® and ASBRIP® in
hospitalized patients infected by SARS-CoV-2 and mild-to-moderate
respiratory illness. An observational prospective study. Clin
Infect Dis. (5)2021.
|
|
44
|
Petrov P, Mihaylov A, Shopove M, Boncheva
M and Marquez D: Efficacy and safety of viusid and asbrip in
hospitalized patients with mild and moderate COVID-19: A randomized
controlled trial. Adv Infectious Dis. 11:171–184. 2021.
|
